Last reviewed · How we verify
Fluzoparib Combined With Apatinib
Fluzoparib is a PARP inhibitor that blocks DNA repair, while apatinib is a VEGFR-2 inhibitor that inhibits angiogenesis, together potentially enhancing antitumor activity.
Fluzoparib is a PARP inhibitor that blocks DNA repair, while apatinib is a VEGFR-2 inhibitor that inhibits angiogenesis, together potentially enhancing antitumor activity. Used for Advanced solid tumors.
At a glance
| Generic name | Fluzoparib Combined With Apatinib |
|---|---|
| Also known as | Apatinib mesylate tablets |
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | PARP inhibitor and VEGFR-2 inhibitor |
| Target | PARP, VEGFR-2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Fluzoparib targets PARP enzymes, which are crucial for repairing single-strand DNA breaks, leading to increased DNA damage and cell death in cancer cells. Apatinib targets VEGFR-2, inhibiting the formation of new blood vessels that support tumor growth.
Approved indications
- Advanced solid tumors
Common side effects
- Fatigue
- Nausea
- Thrombocytopenia
Key clinical trials
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (PHASE2)
- Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer (PHASE3)
- Neoadjuvant SNF Precision Therapy Phase III (PHASE3)
- A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor (NA)
- A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients (PHASE2)
- A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer (PHASE2)
- Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer (PHASE3)
- Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: